tradingkey.logo
搜索

Climb Bio Inc

CLYM
添加自选
11.890USD
-0.630-5.03%
收盘 09-23 16:00(美东)
680.82M总市值
亏损市盈率 TTM

关于 Climb Bio Inc 公司

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Climb Bio Inc 简介

公司代码CLYM
公司名称Climb Bio Inc
上市日期Aug 10, 2021
CEOBrennan (Aoife M)
员工数量17
证券类型Ordinary Share
年结日Aug 10
公司地址20 William Street
城市WELLESLEY HILLS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02481
电话18668572596
网址https://climbbio.com/
公司代码CLYM
上市日期Aug 10, 2021
CEOBrennan (Aoife M)

Climb Bio Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Principal Accounting Officer, Treasurer
Chief Financial Officer, Principal Accounting Officer, Treasurer
--
--
Ms. Perrin Wilson, Ph.D.
Ms. Perrin Wilson, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Carlo Tanzi, Ph.D.
Mr. Carlo Tanzi, Ph.D.
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--

常见问题

Climb Bio Inc的前五大股东是谁?

Climb Bio Inc 的前五大股东如下:Dr. Aoife M. Brennan, M.D.

有多少机构持有Climb Bio Inc(CLYM)的股份?

截至2026Q1,共有194家机构持有Climb Bio Inc的股份,合计持有的股份价值约为35.98M,占公司总股份的59.67%。与2025Q4相比,机构持股有所增加,增幅为-6593711.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有